Attached files

file filename
EXCEL - IDEA: XBRL DOCUMENT - ASSEMBLY BIOSCIENCES, INC.Financial_Report.xls
10-Q - QUARTERLY REPORT - ASSEMBLY BIOSCIENCES, INC.v326006_10q.htm
XML - IDEA: XBRL DOCUMENT - ASSEMBLY BIOSCIENCES, INC.R6.htm
XML - IDEA: XBRL DOCUMENT - ASSEMBLY BIOSCIENCES, INC.R4.htm
XML - IDEA: XBRL DOCUMENT - ASSEMBLY BIOSCIENCES, INC.R8.htm
XML - IDEA: XBRL DOCUMENT - ASSEMBLY BIOSCIENCES, INC.R7.htm
XML - IDEA: XBRL DOCUMENT - ASSEMBLY BIOSCIENCES, INC.R1.htm
XML - IDEA: XBRL DOCUMENT - ASSEMBLY BIOSCIENCES, INC.R2.htm
XML - IDEA: XBRL DOCUMENT - ASSEMBLY BIOSCIENCES, INC.R9.htm
XML - IDEA: XBRL DOCUMENT - ASSEMBLY BIOSCIENCES, INC.R18.htm
XML - IDEA: XBRL DOCUMENT - ASSEMBLY BIOSCIENCES, INC.R17.htm
XML - IDEA: XBRL DOCUMENT - ASSEMBLY BIOSCIENCES, INC.R22.htm
EX-31.1 - CERTIFICATION - ASSEMBLY BIOSCIENCES, INC.v326006_ex31-1.htm
EX-32.1 - CERTIFICATION - ASSEMBLY BIOSCIENCES, INC.v326006_ex32-1.htm
EX-31.2 - CERTIFICATION - ASSEMBLY BIOSCIENCES, INC.v326006_ex31-2.htm
EX-32.2 - CERTIFICATION - ASSEMBLY BIOSCIENCES, INC.v326006_ex32-2.htm
XML - IDEA: XBRL DOCUMENT - ASSEMBLY BIOSCIENCES, INC.R5.htm
XML - IDEA: XBRL DOCUMENT - ASSEMBLY BIOSCIENCES, INC.R13.htm
XML - IDEA: XBRL DOCUMENT - ASSEMBLY BIOSCIENCES, INC.R19.htm
XML - IDEA: XBRL DOCUMENT - ASSEMBLY BIOSCIENCES, INC.R11.htm
XML - IDEA: XBRL DOCUMENT - ASSEMBLY BIOSCIENCES, INC.R15.htm
XML - IDEA: XBRL DOCUMENT - ASSEMBLY BIOSCIENCES, INC.R14.htm
XML - IDEA: XBRL DOCUMENT - ASSEMBLY BIOSCIENCES, INC.R12.htm
XML - IDEA: XBRL DOCUMENT - ASSEMBLY BIOSCIENCES, INC.R20.htm
XML - IDEA: XBRL DOCUMENT - ASSEMBLY BIOSCIENCES, INC.R16.htm
XML - IDEA: XBRL DOCUMENT - ASSEMBLY BIOSCIENCES, INC.R21.htm
XML - IDEA: XBRL DOCUMENT - ASSEMBLY BIOSCIENCES, INC.R3.htm
XML - IDEA: XBRL DOCUMENT - ASSEMBLY BIOSCIENCES, INC.R10.htm
v2.4.0.6
License Agreements - Additional Information (Detail) (S.L.A. Pharma [Member], USD $)
1 Months Ended
Jun. 06, 2011
Aug. 31, 2007
Oct. 09, 2012
Sep. 30, 2012
License Agreement [Member]
       
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Payment to acquire license   $ 1,087,876    
Potential milestone payment     125,000  
Additional services agreement amount       400,000
Potential milestone installment payment 250,000      
Potential milestone payment, number of installments 4      
License Agreement [Member] | Eliminated [Member]
       
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Potential milestone payment 800,000      
License Agreement [Member] | Amendment [Member]
       
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Agreement termination notice period 1 month      
License Agreement [Member] | Maximum [Member]
       
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Potential milestone payment 1,000,000 20,000,000    
Diltiazem Project [Member]
       
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
License agreement, monthly payments   41,500    
Diltiazem Project [Member] | License Agreement [Member]
       
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Development costs 400,000      
Diltiazem Project [Member] | License Agreement [Member] | Maximum [Member]
       
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Total payment obligation under agreement   4,200,000    
Phenylephrine Project [Member]
       
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
License agreement, monthly payments   41,500    
Phenylephrine Project [Member] | License Agreement [Member]
       
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Payment made for services not yet provided       600,000
Phenylephrine Project [Member] | License Agreement [Member] | Maximum [Member]
       
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Potential milestone payment       $ 400,000